Inhibiting menin, a protein known to support the growth of leukemia, may also be an effective strategy for treating myeloproliferative neoplasms (MPNs). New research conducted by scientists at St. Jude Children’s Research Hospital has demonstrated that targeting this protein significantly extended survival rates in preclinical models.
Reversing Disease Features
The study, published today in the journal Cancer Cell, highlights that menin inhibition not only improved longevity but also reversed several key features of the disease. While menin is already a target for certain other forms of leukemia, these findings expand its potential therapeutic application to a broader range of blood cancers.
Preclinical Success
The preclinical success of this approach marks a significant step toward developing new clinical treatments. By disrupting the pathways that allow MPNs to thrive, researchers hope to provide more effective options for patients who currently face limited therapeutic choices.
